Search

Your search keyword '"Salassa, B"' showing total 122 results
Start Over Author "Salassa, B"
122 results on '"Salassa, B"'

3. NEW INSIGHTS INTO CELLULAR FUNCTIONS

Author

Mayorga, L., primary, Salassa, B., additional, Garcia Samartino, C., additional, Loos, M., additional, Eiroa, H., additional, Romano, P., additional, and Roque, M., additional

Published
2018
Full Text
View/download PDF

5. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

Author

Saracino, A, Gianotti, N, Marangi, M, Cibelli, Dc, Galli, A, Punzi, G, Monno, L, Lazzarin, A, Angarano, G, Dini, M, Del Gobbo, R, Montroni, M, Butini, L, Scalise, G, Ancarani, F, Di Cesare, S, Giacometti, A, Biglino, A, Degioanni, M, Paoloni, M, Mariani, R, Calella, G, Pastore, G, Ladisa, N, Mennea, G, Gritti, Fm, Fasullo, G, Chiodo, F, Borderi, M, Carosi, Giampiero, Castelli, Francesco, Torti, Carlo, Uccelli, C, Rizzardini, G, Visoná, R, Salvo, A, Averna, A, Russo, R, Celesia, Bm, Cosentino, S, Rinaldi, E, Pusterla, L, Carnevale, G, Mondello, P, Petrini, C, Ghinelli, F, Sighinolfi, L, Mazzotta, F, Lo Caputo, S, Pierotti, P, Leoncini, F, Sterrantino, Gk, Corsi, P, Pompei, Ag, Di Toro MT, Purificato, F, Indiveri, F, Setti, M, Murdaca, G, Iannessi, A, Cellini, A, Mariani, A, Scasso, A, De Gennaro, M, Chiodera, A, Castelli, P, Maltempo, K, Mongolo, G, Caggese, L, Schlacht, I, Cargnel, A, Atzori, C, Micheli, V, Moroni, M, Bini, T, Marcatto, I, Chiesa, E, Vigevani, G, Argenteri, B, Capetti, A, Esposito, R, Guaraldi, G, Seghetto, B, Chirianni, A, Gargiulo, M, Abrescia, N, D'Abbraccio, M, Busto, T, Marchitelli, C, Santirocchi, M, Abbadessa, V, Mancuso, S, Meneghetti, F, Pranzetti, M, Ferrari, C, Pizzaferri, P, Stagni, G, Di Candilo, F, Petrelli, E, Balducci, M, Menichetti, F, Polidori, M, Tascini, C, Di Carlo, A, Palamara, G, Antinori, A, Liuzzi, G, Aiuti, F, Mezzaroma, I, Pinter, E, Barbone, B, Vullo, V, Massetti, P, Dell'Isola, S, Mura, Ms, Mannazzu, M, Delias, R, Di Giammartino, D, Tarquini, P, Marranconi, F, Ferretto, R, Caramello, P, Orofino, Gc, Cimino, T, Bramato, C, Di Perri, G, Sinicco, A, Zeme, D, Bonora, S, Trentini, L, Soranzo, Ml, Macor, A, Salassa, B, Branz, F, Delle Foglie, P, Vaglia, A, Rossi, Mc, Ciccone, L, Panzolli, L, Grossi, P, Giola, M, Raise, E, Narne, E, Poggio, A, Demin, F, Mondino, V, Serpelloni, G, Malena, M, Bosco, O., Saracino, A, Gianotti, N, Marangi, M, Cibelli, D, Galli, A, Punzi, G, Monno, L, Lazzarin, A, Angarano, G, and Mancuso, S

Subjects
Anti-HIV Agents, DNA Mutational Analysis, Molecular Sequence Data, Proviral DNA, HIV Infections, HAART failure, medicine.disease_cause, DNA Mutational Analysi, chemistry.chemical_compound, HIV Protease, Proviruses, Antiretroviral Therapy, Highly Active, Virology, Drug Resistance, Viral, medicine, Humans, Multicenter Studies as Topic, HIV Infection, Treatment Failure, Genotyping, Randomized Controlled Trials as Topic, COLD-PCR, Mutation, Plasma RNA, biology, Proviruse, Sequence Analysis, RNA, Anti-HIV Agent, RNA, Sequence Analysis, DNA, biology.organism_classification, HIV Reverse Transcriptase, Reverse transcriptase, Antiretroviral genotypic resistance, Infectious Diseases, chemistry, DNA, Viral, Lentivirus, Immunology, HIV-1, RNA, Viral, DNA, antiretroviral genotypic resistance, haart failure, hiv-1, plasma rna, proviral dna, Human
Abstract

The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was significantly higher in RNA (4.45 ± 2.76) than in DNA (2.88 ± 2.47) (P < 0.001). DNA genotyping provided a 6% increase in detection of resistance-associated mutations. Among 64/73 patients showing discordant DNA/RNA profiles, 54 (84%) also differed for predicted active drugs. 16/73 (22%) patients had ≥1 mutation revealed by DNA genotyping alone, probably affecting therapy success in 2/16. However, neither RNA/DNA discordance nor detection of isolated DNA mutations were statistically associated with outcome. In conclusion, plasma RNA remains the elective choice for HIV genotyping in patients with therapy failure, even if the detection of proviral resistance-associated mutations, not simultaneously found in RNA, is a frequent event. Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens. © 2008 Wiley-Liss, Inc.

Published
2008

11. Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection

Author

E. Chiaberge, Maria Luisa Soranzo, Spezia C, Enrica Pessione, Ferruccio Bonino, C Lavarini, Salassa B, Maurizia Rossana Brunetto, Floriano Rosina, Antonina Smedile, Enrica Daziano, and C. Bramato

Subjects
Adult, Male, Hepatitis B virus, viruses, Immunoblotting, Radioimmunoassay, medicine.disease_cause, Virus, Humans, Medicine, Serologic Tests, Hepatitis, Hepatitis B Surface Antigens, Hepatology, biology, business.industry, Nucleic Acid Hybridization, virus diseases, RNA Probes, Hepatitis B, medicine.disease, Hepatitis D, Virology, Immunoglobulin M, biology.protein, Coinfection, RNA, Viral, Female, Viral disease, Hepatitis Delta Virus, business
Abstract

Diagnosis of acute hepatitis B virus/hepatitis delta virus (HBV/HDV) coinfection is currently based on detection of anti-HD, however this antibody may be undetectable during the acute phase of hepatitis. To evaluate the entity of misdiagnosis of HBV/HDV coinfection in acute HBsAg-anti-HBc IgM positive hepatitis we examined sera from 245 consecutive patients obtained at admission and day 30, 60, 120, 210 and 400 of their follow-up. Anti-HD was detected in the serum of 26 out of 245 patients (10.6%). In 15% of cases it was present at admission, while in 92% it was found after 30 days. The combined detection of HDV-RNA, HDAg and IgM anti-HD in acute phase sera allowed a correct etiologic diagnosis in 69% of the cases. These findings suggest that the prevalence of HBV/HDV coinfection is underestimated when anti-HD is the only marker to be detected during the acute phase of disease. A correct etiologic diagnosis can only be made by testing acute phase sera for all the available markers of HDV. However, the best cost-effective procedure is to test any patient with HBV markers at presentation for anti-HD, 30-40 days after the onset of symptoms.

Published
1991

12. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study

Author

Palmisano, L., Giuliano, M., Bucciardini, R., Fragola, V., Andreotti, M., Galluzzo, C. M., Pirillo, M. F., Weimer, L. E., Arcieri, R., Germinario, E. A. P., Amici, R., Mancini, M. G., D'Arminio Monforte, A., Castelli, F., Caramello, P., Vella, S., Abrescia, N., Figoni, M., Viglietti, R., Angarano, G., Saracino, A., Anselmo, M., Antinori, A., Sette, P., Zaccarelli, M., Liuzzi, G., Arlotti, M., Martelli, L. T., Ortolani, P., Bassetti, D., Di Biagio, A., Bisio, F., Bellissima, P., Branz, F., Dorigoni, N., Cadeo, G., Vangi, D., Bertelli, D., Bergamasco, A., Caggese, L., Volonterio, A., Orofino, G. C., Carosella, S., Gennero, L., Caremani, M., Tacconi, D., Carosi, G., Tomasoni, L., Patroni, A., Chiodo, F., Borderi, M., Calza, L., Gritti, F., Fasulo, G., Chirianni, A., Gargiulo, M., Colomba, A., Dalle Nogare, E. R., Di Lorenzo, F., Prestileo, T., Bini, T., Cicconi, P., De Lalla, F., Giordani, M. T., De Stefano, C., De Stefano, G., Delia, S., Ciardi, M., Di Perri, G., Sinicco, A., Sales, P., Dini, M., Simeone, M., Esposito, R., Guaraldi, G., Beghetto, B., Fatuzzo, F., La Rosa, R., Ferrari, C., Calzetti, C., Ferraro, T., Cosco, L., Ghinelli, F., Sighinolfi, L., Guadagnino, V., Caroleo, B., Izzi, A., Izzo, C., Franco, A., Lazzarin, A., Castagna, A., Fusetti, G., Leoncini, F., Pozzi, M., Sbaragli, S., Marzetti, M., Magnani, G., Bonazzi, L., Barchi, E., Zoboli, G., Pintus, A., Mandas, A., Soddu, M. L., Zucca, F., Mannucci, P. M., Gringeri, A., Marani Toro, G., Graziani, R. V., Consorti, A., Mazzotta, F., Di Pietro, M., Ble, C., Meneghetti, F., Sasset, L., Cattelan, A. M., Menichetti, F., Savalli, E., Mian, P., Pristera, R., Mignani, E., Artioli, S., Mura, M. S., Mannazzu, M., Narciso, P., Bellagamba, R., Orani, A., Perini, P., Ortona, L., De Luca, A., Murri, R., Pagano, G., Alessandrini, A., Paladini, A., Vinattieri, M. A., Carbonai, S., Pastore, G., Ladina, N., Tateo, M., Piersantelli, N., Penco, G., Petrelli, E., Balducci, M., Pippi, L., Gonnelli, A., Puppo, F., Murdaca, G., Raise, E., Pasquirucci, A., Riccio, G., Bartolacci, V., Carrega, G., Rizzardini, G., Migliorino, G., Russo, R., Casentino, S., Celesia, M., Soranzo, M. L., Macor, A., Salassa, B., Soscia, F., Roberti, L., Di Toro, M. T., Stagno, A., Beltrami, C., Suter, F., Maggiolo, F., Ripamonti, D., Tantimonaco, G., Grisorio, B., Tassara, A., Rossi, P., Tinelli, M., Regazzetti, A., Tirelli, U., Voltaggio, G., Cinelli, R., Toti, M., Baldari, M., Carli, T., Ricciardi, B., Trezzi, M., Vigevani, G. M., Capetti, A., Landonio, S., Vullo, V., Massetti, P., Zauli, T., and Casolari, S.

Subjects
Adult, Male, medicine.medical_specialty, Anti-HIV Agents, medicine.medical_treatment, HIV Infections, Drug resistance, Drug Administration Schedule, law.invention, Randomized controlled trial, Drug Resistance, Multiple, Viral, law, Internal medicine, medicine, Humans, Pharmacology (medical), Protease inhibitor (pharmacology), Structured treatment interruptions, Chemotherapy, Reverse-transcriptase inhibitor, biology, business.industry, HIV, Middle Aged, biology.organism_classification, CD4 Lymphocyte Count, Clinical trial, Chronic infection, Regimen, Infectious Diseases, Immunology, Lentivirus, RNA, Viral, Female, business, medicine.drug
Abstract

Background: Factors influencing the outcome of structured treatment interruptions (STIs) in HIV chronic infection are not fully elucidated. Methods: In ISS-PART, 273 subjects were randomly assigned to arm A (137 assigned to continuous highly active antiretroviral therapy [HAART]) and arm B (136 assigned to 5 STIs of 1, 1, 2, 2, and 3 months'duration, each followed by 3 months of therapy). Main outcome measures were the proportion of subjects with a CD4 count >500 cells/mm 3 , the rate of virologic failure, and the emergence of resistance at 24 months. Results: The proportion of subjects with a CD4 count >500 cells/mm 3 was higher in arm A than in arm B (86.5% vs. 69.1%; P = 0.0075). Pre-HAART CD4 cell count and male gender were independent predictors of a CD4 count >500 cells/mm 3 in arm B. The overall risk of virologic failure was not increased in arm B; however, it was higher in the 38 subjects who had resistance mutations in the rebounding virus. Archived mutations at baseline and the use of a regimen that included an unboosted protease inhibitor (PI), compared with nonnucleoside reverse transcriptase inhibitor-based HAART, independently predicted the emergence of plasma mutations during STI (P = 0.002 for DNA mutations and P = 0.048 for PI-based HAART). Conclusions: Our results suggest that patients with preexisting mutations and treated with unboosted PI-based HAART should not be enrolled in studies of time-fixed treatment interruptions, being at higher risk of developing plasma mutations during STI and virologic failure at therapy reinstitution.

Published
2007

13. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy

Author

Girardi, E., Antonucci, G., Vanacore, P., Palmieri, F., Matteelli, A., Iemoli, E., Carradori, S., Salassa, B., Pasticci, M. B., Raviglione, M. C., Ippolito, G., Babudieri, S., Bassetti, M., Rosso, R., Carbonara, S., Celesia, B. M., Chirianni, A., Di Perri, G., Fabietti, P., Gabutti, A., Guadagnino, V., Manfrin, V., Zacchini, F., Burzacchini, F., Giacometti, A., Tassara, A., Traverso, A., Giorni, P., Gobbi, M., Mariani, R., Di Gennaro, G., Panella, L., Losappio, R., Beltrami, C., Costigliola, P., Fasulo, G., Moling, O., Bertelli, D., Tedoldi, S., Potenza, D., Manconi, P. E., Zichichi, S., Nacca, C., Fatuzzo, F., La Rosa, R., Galvagna, S., Grosso, C., Vecchiet, J., Longoni, E., Guaglianone, L., Pan, A., Pellicano, S., Raineri, G., Ferrara, S., Anzalone, E., Gallo, A., Cataldini, S., Dodi, F., Petronio, A., Salone, G., De Luca Andrioli, E. P., De Checchi, G., Villa, M., Pardelli, R., Tardio, A., Urbani, C., Gattuso, G., Matini, L., Casciano, G., Loschiavo, F., Errante, I., Giani, G., Meraviglia, P., Molteni, C., Guaraldi, G., Foresti, S., Abbrescia, N., Izzo, C., Filippini, P., Noce, S., Dalle Nogare, E. R., Farinella, E., Sacchi, P., Scudeller, L., Petrelli, E., Alterio, L., Paolillo, F., Savalli, E., Doria, R., Catalani, M., Brizzi, M., Storaci, N., Natalini Raponi, G. P., Martelli, L. T., Grisetti, S., Lanini, S., and Santopadre, P.

Subjects
Male, Epidemiology, Antitubercular Agents, Severity of Illness Index, Cohort Studies, Antiretroviral Therapy, Highly Active, Prospective Studies, Sida, biology, Incidence (epidemiology), Incidence, Antiretroviral therapy, HIV infection, Italy, Multicenter study, Tuberculosis, AIDS-Related Opportunistic Infections, Adult, Age Distribution, Chi-Square Distribution, Female, Follow-Up Studies, Humans, Logistic Models, Middle Aged, Sex Distribution, Statistics, Nonparametric, Survival Rate, Treatment Outcome, Tuberculosis, Pulmonary, Statistics, virus diseases, Pulmonary, Cohort study, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Antiretroviral Therapy, Context (language use), Acquired immunodeficiency syndrome (AIDS), Tuberculosis diagnosis, Internal medicine, medicine, Highly Active, Nonparametric, business.industry, medicine.disease, biology.organism_classification, Immunology, business
Abstract

Highly active antiretroviral therapy (HAART) greatly reduces the risk of developing tuberculosis for HIV-infected persons. Nonetheless, HIV-associated tuberculosis continues to occur in countries where HAART is widely used. To identify the characteristics of HIV-infected persons who develop tuberculosis in the context of the availability of HAART, the current authors analysed data taken from 271 patients diagnosed, in Italy, during 1999-2000. These patients represent 0.7% of the 40,413 HIV-infected patients cared for in the clinical units participating in this current study. From the data it was observed that 20 patients (7.4%) had a previous episode of tuberculosis whose treatment was not completed. Eighty-one patients (29.9%) were diagnosed with HIV at tuberculosis diagnosis, 108 (39.8%) were aware of their HIV status but were not on antiretroviral treatment and 82 (30.3%) were on antiretroviral treatment. Patients on antiretroviral treatment were significantly less immunosuppressed than patients with HIV diagnosed concurrently with tuberculosis, or other patients not on antiretrovirals (median CD4 lymphocytes count: 220 cells x mm(-3) versus 100 cells x mm(-3), and 109 cells x mm(-3), respectively). No significant differences in clinical presentation of tuberculosis according to antiretroviral therapy status were recorded. Failure of tuberculosis control interventions (e.g. noncompletion of treatment) and of HIV care (delayed diagnosis of HIV infection and suboptimal uptake of therapy) may contribute to continuing occurrence of HIV-associated tuberculosis in a country where highly active antiretroviral therapy is largely available. However, a significant proportion of cases occur in patients who are on antiretroviral treatment.

Published
2004

14. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]

Author

Pezzotti, P, Dorrucci, M, Donisi, A, Cusini, M, Mazzarello, G, De Luca, Andrea, Salassa, B, Ursitti, Ma, Giuliani, M, and Rezza, G.

Subjects
Adult, CD4-Positive T-Lymphocytes, Immunosuppression Therapy, Male, Acquired Immunodeficiency Syndrome, Time Factors, Age Factors, Antiretroviral Therapy, Middle Aged, Settore MED/17 - MALATTIE INFETTIVE, Survival Analysis, Cohort Studies, Risk Factors, Antiretroviral Therapy, Highly Active, HIV Seropositivity, Disease Progression, Humans, Highly Active, Female, Controlled Clinical Trials as Topic, Prospective Studies, Immunosuppression, Follow-Up Studies, Proportional Hazards Models
Abstract

We evaluated the changes in the progression to death and AIDS and in the mean level of CD4 lymphocytes by calendar period in HIV-positive individuals before and after the introduction of HAART. Through data collected in a prospective cohort study (Italian Seroconversion Study) of 1899 HIV-infected persons with well estimated date of seroconversion, considered as time-zero of analysis, we calculated Kaplan-Meier curves and Cox models, allowing for staggered entries, to estimate the cumulative probability of survival and hazard-ratios (HR) for death and for AIDS by calendar period (1980-1996: pre-HAART era, 1997-1998: first HAART era, and 1999-2001: second HAART era), age at seroconversion, gender, and exposure category. During 17251 person-years, 660 HIV-positive patients developed AIDS and 510 died. Before 1997, the cumulative probability of survival, at twelve years from seroconversion, was 51.0%. In the period 1997-1998 the probability was 77.3% and in the period 1999-2001 it further increased at 91.2%. In the period 1980-1996 only older age at seroconversion was associated with more rapid progression to death. In the period 1987-2001 individuals infected through injecting drug use had a reduced increase of survival compared to those infected through sexual contact. Similar results were obtained for progression to AIDS. Finally we estimated an improved level of immunesuppression in the period 1987-2001. In fact, while in the period 1980-1996 we estimated a decrease of the CD4 lymphocites of -54.8 cells/mm3 (95% CI: -52.0; -57.6) per year; after 1996, we estimated an increase of CD4 of +39.6 (95% CI +34.1; +45.1)per year. This study provides strong evidence that the efficacy of the HAART estimated in the controlled clinical trials has resulted in a real reduction at the population level of morbidity and mortality.

Published
2004

15. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

Author

Cozzi-Lepri, Alessandro, Phillips, Andrew N., D'Arminio Monforte, Antonella, Piersantelli, Nicoloò, Orani, Anna, Petrosillo, Nicola, Leoncini, Francesco, Scerbo, Antonio, Tundo, Paolo, Abrescia, Nicola, Montroni, M., Scalise, G., Costantini, Alessia, Del Prete, M. S., Tirelli, U., Nasti, G., Pastore, G., Ladisa, N., Perulli, L. M., Suter, F., Arici, C., Chiodo, F., Gritti, F. M., Colangeli, V., Fiorini, C., Guerra, L., Carosi, G., Cadeo, G. P., Castelli, F., Minardi, C., Vangi, D., Rizzardini, G., Migliorino, G., Manconi, P. E., Piano, P., Ferraro, T., Scerbo, A., Pizzigallo, E., Ricci, Fiammetta, Rinaldi, E., Pusterla, L., Carnevale, G., Galloni, D., Viganò, P., Mena, M., Ghinelli, F., Sighinolfi, L., Leoncini, F., Mazzotta, F., Ambu, S., Lo Caputo, S., Angarano, G., Grisorio, B., Ferrara, S., Grima, P., Tundo, P., Pagano, G., Piersantelli, N., Alessandrini, A., Piscopo, R., Toti, M., Chigiott, S., Soscia, F., Tacconi, L., Orani, A., Castaldo, G., Scasso, A., Vincenti, A., Scalzini, A., Alessi, F., Moroni, M., Lazzarin, A., Cargnel, A., Vigevani, G. M., Caggese, L., d’Arminio Monforte, A., Bongiovanni, M., Novati, R., Delfanti, F., Merli, S., Pastecchia, C., Moioli, C., Esposito, R., Mussini, C., Abrescia, N., Chirianni, A., Izzo, OMAR CARLO ENRICO, Piazza, M., De Marco, M., Montesarchio, V., Manzillo, E., Nappa, S., Colomba, A., Abbadessa, V., Prestileo, T., Mancuso, S., Filice, G., Minoli, L., Bruno, R., Maserati, R., Pauluzzi, S., Tosti, A., Alberici, F., Sisti, M., Menichetti, F., Smorfa, A., De Stefano, C., Lagala, A., Zauli, T., Ballardini, G., Bonazzi, L., Ursitti, M. A., Ciammarughi, R., Ortolani, P., Ortona, L., Dianzani, F., Antinori, A., Antonucci, G., D’Elia, S., Ippolito, G., Narciso, P., Petrosillo, N., Rezza, G., Vullo, V., De Luca, A., Del Forno, A., Capobianchi, M. R., Zaccarelli, M., De Longis, P., Ciardi, M., Girardi, E., D’Offizi, G., Noto, P., Pezzotti, P., Bugarini, R., Lichter, M., Mura, M. S., Mannazzu, M., Caramello, P., Caramello, A., Soranzo, M. L., Gennero, L., Sciandra, M., Salassa, B., Grossi, P. A., Basilico, C., Poggio, A., Bottari, G., Raise, E., Pasquinucci, S., De Lalla, F., Tositti, G., Resta, F., and Chimienti, A.

Subjects
Cyclopropanes, Adult, Male, medicine.medical_specialty, Efavirenz, Nevirapine, Settore MED/17 - Malattie Infettive, Adolescent, Antiretroviral Therapy, Pharmacology, Efficacy, Cohort Studies, chemistry.chemical_compound, Drug Therapy, Antiretroviral Therapy, Highly Active, Internal medicine, Oxazines, medicine, Humans, Immunology and Allergy, Highly Active, Viral, Sida, Aged, Acquired Immunodeficiency Syndrome, biology, Reverse-transcriptase inhibitor, business.industry, Middle Aged, biology.organism_classification, Confidence interval, Benzoxazines, CD4 Lymphocyte Count, Infectious Diseases, chemistry, Alkynes, Cohort, Combination, RNA, Viral, RNA, Drug Therapy, Combination, Female, business, Cohort study, medicine.drug
Abstract

This nonrandomized study compared the virologic and immunologic responses to potent regimens containing either efavirenz or nevirapine after considering potential systematic differences between patients receiving these drugs. Virologic failure was defined as the first of 2 consecutive measurements of virus load >500 human immunodeficiency virus RNA copies/mL. Of the 694 patients included in the analysis, 460 (66.3%) started nevirapine and 234 (33.7%) started efavirenz. The adjusted relative hazard of virologic failure for patients who started nevirapine, compared with those who started efavirenz, was 2.08 (95% confidence interval, 1.37-3.15; P=.0006). In addition, patients receiving efavirenz tended to recover 5 CD4 cells/microL more per quarter (P=.05). Although comparisons of drug efficacy in nonrandomized studies should be viewed with caution, no results from randomized controlled comparisons of these drugs are thought to be available. The findings of this study are in agreement with those of other observational studies.

Published
2002

17. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function

Author

Calcagno, A., primary, Gonzalez de Requena, D., additional, Simiele, M., additional, D'Avolio, A., additional, Tettoni, M. C., additional, Salassa, B., additional, Orofino, G., additional, Bramato, C., additional, Libanore, V., additional, Motta, I., additional, Bigliano, P., additional, Orsucci, E., additional, Di Perri, G., additional, and Bonora, S., additional

Published
2013
Full Text
View/download PDF

19. Lo studio di coorte I.CO.N.A. (Italian CohOrt Naive Antiretrovirals): caratteristiche all’arruolamento dei primi 1676 soggetti

Author

DARMINIO MONFORTE, A, Arici, C, Ippolito, G., Rezza, G., Angarano, G., Carosi, G., Vhiodo, F., Dianzani, F., Di Luzio Paparatti, U., Lazzarin, A., Ortona, L., Garattini, L., Musicco, M., Pezzotti, P., Vella, S., Abrescia, N., Aceti, A., Alberici, F., Armignacco, O., Bonazzi, L., Cadeo, G. P., Cadrobbi, P., Caggese, L., Cargnel, A., Carnevale, G., Chirianni, A., Ciammarughi, R., Colomba, A., D'Amato, C., De Lalla, F., D'Elia, S., Dealla Santa, M., De Rienzo, B., De Stefano, C., Ferraro, T., Filice, G., Fiori, G. P., Gavazzeni, G., Ghinelli, F., Gioannini, P., Grilone, W., Grima, P., Grisorio, B., Gritti, F. M., Leoncini, F., Manconi, P. E., Mazzotta, F., Milazzo, F., Minoli, L., Montroni, M., Narciso, P., Orani, A., Pauluzzi, S., Piazza, M., Piersantelli, N., Pizzigallo, E., Poggio, A., Reaise, E., Ranieri, S., Resta, F., Rizzo, F., Rosci, M. A., Scalise, G., Scalzini, A., Scasso, A., Soranzo, M. L., Soscia, F., Suter, F., Tirelli, U., Toti, M., Viganò, P., Vigevani, G. M., Vullo, V., Ravasio, L., Girardi, E., Federico, M. D., Castelli, Francesco, Colangeli, V., Capobianchi, M., Sinnone, M. S., Antinori, A., Boccia, L., Mannazzu, M., Sisti, M., DE LOngis, P., Ursitti, M. A., Vangi, D., Scaggiante, R., Moioli, M. C., Adriani, B., Pan, A., Montesarchio, M., Arlotti, M., Prestileo, T., Palmieri, F., Franzetti, M., Ciardi, M., Smorfa, A., Mussini, C., Armignacco, L., Cosco, L., Patruno Savino, F. A., Torre, D., Sighinolfi, L., Sciandra, M., Giacobbi, D., Tundo, P., Ferrara, S., Guerra, L., Ambu, S., Piano, P., Lo Caputo, S., Rizzardini, G., Maserati, R., Costantini, A., D'Offizi, G. P., Castaldo, G., Tosti, A., Nappa, S., Piscopo, R., Ricci, F., Bottari, V., Pasquinucci, S., Ballardini, G., Chimienti, A., Alessandrini, A., Zaccarelli, M., Del Prete, M. S., Costa, P., Vincenti, A., Salassa, B., Tacconi, L., Bottura, P., Nasti, G., Incandela, L., Ghiselli, G. C., Pusterla, L., Lichtner, M., and Moroni, M.

Published
1997

20. Markers of response to zidovudine monotherapy among treated HIV seroconverters

Author

Rezza, G, Galay, N, Pezzotti, P, Vlahov, D, Graham, N, Viale, P. L., Angarano, G., Dorrucci, M., Alliegro, M. B., Cozzi Lepri, A., Sinicco, A., Lazzarin, A., Tarantini, G., Zrboni, R., Rosso, Rm, Aqiuti, F, Salassa, B, Pristerà, R, Gafà, S, Colangeli, V, Canessa, A, Barbanera, M, Alberici, F, Castelli, Francesco, Zaccarelli, M, Ortona, L, and Tirelli, U.

Published
1997

21. Analysis of determinants of long‐term efficacy of unboosted atazanavir‐based regimens in the clinical setting

Author

Bonora, S, Calcagno, A, Viganò, O, Bigliano, P, Rusconi, S, Trentini, L, Tettoni, Mc, Orofino, G, Salassa, B, Bramato, C, D' Avolio, A, Siccardi, M, Colella, E, Galli, M, and Di Perri, G

Subjects
Atazanavir -- Dosage and administration -- Patient outcomes, HIV infection -- Drug therapy -- Patient outcomes, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Background Switch to unboosted atazanavir (ATV 400 mg qd), although not licensed in Europe, is an attractive off‐label option due to convenience and tolerability. However there is a substantial lack [...]

Published
2010
Full Text
View/download PDF

22. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]

Author

Pezzotti, P, Dorrucci, M, Donisi, A, Cusini, M, Mazzarello, G, De Luca, Andrea, Salassa, B, Ursitti, Ma, Giuliani, M, Rezza, G., De Luca, Andrea (ORCID:0000-0002-8311-6935), Pezzotti, P, Dorrucci, M, Donisi, A, Cusini, M, Mazzarello, G, De Luca, Andrea, Salassa, B, Ursitti, Ma, Giuliani, M, Rezza, G., and De Luca, Andrea (ORCID:0000-0002-8311-6935)

Abstract

We evaluated the changes in the progression to death and AIDS and in the mean level of CD4 lymphocytes by calendar period in HIV-positive individuals before and after the introduction of HAART. Through data collected in a prospective cohort study (Italian Seroconversion Study) of 1899 HIV-infected persons with well estimated date of seroconversion, considered as time-zero of analysis, we calculated Kaplan-Meier curves and Cox models, allowing for staggered entries, to estimate the cumulative probability of survival and hazard-ratios (HR) for death and for AIDS by calendar period (1980-1996: pre-HAART era, 1997-1998: first HAART era, and 1999-2001: second HAART era), age at seroconversion, gender, and exposure category. During 17251 person-years, 660 HIV-positive patients developed AIDS and 510 died. Before 1997, the cumulative probability of survival, at twelve years from seroconversion, was 51.0%. In the period 1997-1998 the probability was 77.3% and in the period 1999-2001 it further increased at 91.2%. In the period 1980-1996 only older age at seroconversion was associated with more rapid progression to death. In the period 1987-2001 individuals infected through injecting drug use had a reduced increase of survival compared to those infected through sexual contact. Similar results were obtained for progression to AIDS. Finally we estimated an improved level of immunesuppression in the period 1987-2001. In fact, while in the period 1980-1996 we estimated a decrease of the CD4 lymphocites of -54.8 cells/mm3 (95% CI: -52.0; -57.6) per year; after 1996, we estimated an increase of CD4 of +39.6 (95% CI +34.1; +45.1)per year. This study provides strong evidence that the efficacy of the HAART estimated in the controlled clinical trials has resulted in a real reduction at the population level of morbidity and mortality.

Published
2003

23. Immunologic markers of AIDS progression - consistency across 5 HIV-infected cohorts: multicohort analysis project workshop, part 1

Author

Bird, G., Cook, R., Deangelis, D., Farewell, V., Fielding, K., Fore, A., Gore, S., Krämer, Alexander, Lee, C., McNeil, A., Pezzotti, P., Phillips, A., Raboud, J., Rezza, G., Sabin, C., Satten, G., Brettle, Cr., Hamilton, B., Povey, S., Raab, G., Richardson, A., Aiuti, F., Angarano, G., Barbanera, M., Canessa, A., Castelli, F., Gafa, S., Lazzarin, A., Muratori, S., Pristera, R., Ricchi, E., Salassa, B., Sinicco, A., Tirelli, U., Viale, P., Zaccarelli, M., Bofill, M., Elford, J., Janossy, G., Goedert, James J., Yellin, F., Coates, R., Calzavarra, L., and Reid, S.

Subjects
AIDS progression, cofactors, Immunologic markers, zidovudine use
Published
1994

24. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and [beta]2-microglobulin are not adequate to estimate time of HIV infection: multicohort analysis project workshop, part 2

Author

Bird, G., Cook, R., Deangelis, D., Farewell, V., Fielding, K., Fore, A., Gore, S., Krämer, Alexander, Lee, C., McNeil, A., Pezzotti, P., Phillips, A., Raboud, J., Rezza, G., Sabin, C., Satten, G., Brettle, Cr., Hamilton, B., Povey, S., Raab, G., Richardson, A., Aiuti, F., Angarano, G., Barbanera, M., Canessa, A., Castelli, F., Gafa, S., Lazzarin, A., Muratori, S., Pristera, R., Ricchi, E., Salassa, B., Sinicco, A., Tirelli, U., Viale, P., Zaccarelli, M., Bofill, M., Elford, J., Janossy, G., Goedert, James J., Yellin, F., Coates, R., Calzavarra, L., and Reid, S.

Subjects
single sample discrimination, cofactors, Immunologic marker paths
Published
1994

25. Storia naturale della infezione da HIV nelle donne

Author

Dorrucci, M., Rezza, G., Pezzotti, P., Lazzarin, A., Angarano, G., Sinicco, A., Zerboni, R., Aiuti, F., Pristera, R., Gafà, S., Castelli, Francesco, Salassa, B., Barbanera, M., Canessa, A., Ortona, L., Costigliola, P., Viale, P., Tirelli, U., Zaccarelli, M., Alliegro, B., and Lo Caputo, S.

Published
1993

27. AIDS-related knowledge and behaviours among teen-agers, Italy, 1990

Author

Lorenzetti, P, Rossi, P, Armignacco, L, DE STEFANO, C, Ferrara, P, Iannicelli, G, Sangalli, M, Zaccarelli, M, Belloni, A, Castelli, Francesco, Parisi, A., Morandi, N, Morando, A., Stagnaro, R., Amati, M., Battucci, S., Beretta, A., Paggi, G., Salassa, B., Germinario, C., Iacobellis, O., Lo Caputo, S., Aiazzi, C., Milio, D., Rubino, M., Scasso, A., Gosetti, G., Alongi, M., Arpaia, D., Cicconi, G., De Zardo, F., Napolitani, E., Greco, D., Pezzotti, P., Salmaso, S., and Tozzi, A.

Published
1991

28. Adolescenti e infezione da HIV. Uno studio di conoscenza, attitudine comportamenti dei giovani

Author

Tozzi, A. E., Binkin, N, Salmaso, S, Pezzotti, P, Greco, D, Aiazzi, C, Amati, M. P., Armignacco, L, Battucci, S, Belloni, A. M., BERETTA ANGUISSOLA, M, Castelli, Francesco, mDe Stefano, C., Ferrara, P., Germinario, C., Gosetti, G., Iacobellis, O., Iannicelli, G., Lo Caputo, S., Lorenzetti, P., Milo, D., Morandi, N., Morando, A., Paggi, G., Parisi, A., Rossi, P., Rubino, M., Salassa, B., Sangalli, M., Scasso, A., Stagnaro, R., and Zaccarelli, M.

Published
1991

29. Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sarcoma and Other Acquired Immunodeficiency Syndrome-Related Diseases

Author

Rezza, G., primary, Andreoni, M., additional, Dorrucci, M., additional, Pezzotti, P., additional, Monini, P., additional, Zerboni, R., additional, Salassa, B., additional, Colangeli, V., additional, Sarmati, L., additional, Nicastri, E., additional, Barbanera, M., additional, Pristera, R., additional, Aiuti, F., additional, Ortona, L., additional, and Ensoli, B., additional

Published
1999
Full Text
View/download PDF

30. Tuberculin survey among hospital workers in Turin (Italy)

Author

Bugiani, M., primary, Cavallero, M., additional, Piccioni, P., additional, Carosso, A., additional, Arossa, W., additional, Luccoli, L., additional, Coscia, G.C., additional, DalConte, I., additional, Salassa, B., additional, and Silvaplana, P., additional

Published
1994
Full Text
View/download PDF

32. Epidemic Kaposi’s sarcoma in Italy, a country with intravenous drug users as the main group affected by HIV infection

Author

Tirelli, U., primary, Vaccher, E., additional, Lazzarin, A., additional, Errante, D., additional, Alessi, E., additional, Crosato, I., additional, Spina, M., additional, Zaccarelli, M., additional, Aiuti, F., additional, Moroni, M., additional, Monfardini, S., additional, Greco, D., additional, Ancarani, F., additional, Angarano, G., additional, Baroni, C., additional, Borri, A., additional, Barelli, A., additional, Cagnoni, G., additional, Cajozzo, A., additional, Carbone, A., additional, Cargnel, A., additional, Confalonieri, F., additional, Costigliola, P., additional, Crocchiolo, P., additional, De Agostini, A., additional, Santa, M. Della, additional, Fasan, M., additional, Figoli, F., additional, Fiore, G.P., additional, Garavelli, P.L., additional, Giannelli, F., additional, Galâ, S., additional, Giudici, M.G., additional, Gritti, F.M., additional, Luzi, G., additional, Luzzati, R., additional, Magnani, G., additional, M., Malena, additional, Malfitano, A., additional, Mazzotta, F., additional, Meraviglia, P., additional, Milazzo, F., additional, Milo, D., additional, Ortona, L., additional, Paladini, A., additional, Piersantelli, N., additional, Pristerà, R., additional, Raineri, G., additional, Raise, E., additional, Repetto, L., additional, Rezza, G., additional, Rinaldi, E., additional, Ricchi, E., additional, Riccio, G., additional, Rizzardini, G., additional, Rizzi, M., additional, Rizzo, F., additional, Rosso, R., additional, Salassa, B., additional, Saliva, G., additional, Savalli, E., additional, Scalise, G., additional, Scasso, A., additional, Sinicco, A., additional, Soranzo, M.L., additional, Stellini, R., additional, Sueri, L., additional, Sulis, E., additional, Suter, F., additional, Terragna, A., additional, Troiano, T., additional, Vaglia, A., additional, Visco, G., additional, Foà, R., additional, and Gavosto, F., additional

Published
1991
Full Text
View/download PDF

33. Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection

Author

Salassa, B., primary, Daziano, Enrica, additional, Bonino, F., additional, Lavarini, Carla, additional, Smedile, Antonina, additional, Chiaberge, Elisabetta, additional, Rosina, F., additional, Brunetto, Maurizia Rossana, additional, Pessione, Enrica, additional, Spezia, C., additional, Bramato, C., additional, and Soranzo, Maria Luisa, additional

Published
1991
Full Text
View/download PDF

34. Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

Author

Perno, Carlo Federico, Cozzi-Lepri, Alessandro, Balotta, Claudia, Forbici, Federica, Violin, Michela, Bertoli, Ada, Facchi, Guido, Pezzotti, Patrizio, Angarano, Gioacchino, Arici, Claudio, Narciso, Pasquale, Orani, Anna, Raise, Enzo, Scalzini, Alfredo, Poggio, Antonio, Ippolito, Giuseppe, Moroni, Mauro, Monforte, Antonella d'Arminio, Montroni, M, Scalise, G, Costantini, A, Del Prete, MS, Tirelli, U, Nasti, G, Pastore, G, Perulli, LM, Suter, F, Arici, C, Chiodo, F, Gritti, FM, Colangeli, V, Fiorini, C, Guerra, L, Carosi, G, Cadeo, GP, Castelli, F, Minardi, C, Vangi, D, Rizzardini, G, Migliorino, G, Manconi, PE, Piano, P, Ferraro, T, Cosco, L, Pizzigallo, E, Ricci, F, Vigevani, GM, Pusterla, L, Carnevale, G, Pan, A, Viganò, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Ambu, S, Lo Caputo, S, Angarano, G, Grisorio, B, Ferrara, S, Grima, P, Tundo, P, Pagano, G, Piersantelli, N, Alessandrini, A., Piscopo, R., Toti, M, Chigiotti, Soscia, F, Tacconi, L, Orani, A, Castaldo, G, Scasso, A, Vincenti, A, Scalzini, A, Alessi, F, Moroni, M, Lazzarin, A, Cargnel, A, Milazzo, F, Caggese, L, Monforte, A d'Arminio, Melzi, S, Delfanti, F, Carini, B, Adriani, B, Garavaglia, S, Moioli, C, Esposito, R, Mussini, C, Abrescia, N, Chirianni, A, Perrella, O, Piazza, M, De Marco, M, Montesarchio, V, Manzillo, E, Nappa, S, Cadrobbi, P, Scaggiante, R, Colomba, A, Abbadesse, V, Prestileo, T, Mancuso, S, Filice, G, Minoli, L, Savino, FA Patruno, Maserati, R, Pauluzzi, S, Baldelli, F, Petrelli, E, Ciotti, A, Alberici, F, Sisti, M, Menichetti, F, Smorfa, A, De Stefano, C, La Gala, A, Zauli, T, Ballardini, G, Bonazzi, L, Ursitti, MA, Ciammarughi, R, Giordani, S, Ortona, L, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, D'Elia, S, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Del Forno, A, Zaccarelli, M, De Longis, P, Ciardi, M, D'Offizi, G, Palmieri, F, Lichter, M, Capobianchi, MR, Girardi, E, Pezzotti, P, Rezza, G, Mura, MS, Mannazzu, M, Caramello, P, Sinicco, A, Soranzo, ML, Quaglia, S, Sciandra, M, Salassa, B, Torre, D, Basilico, C, Poggio, A, Bottari, G, Raise, E, Pasquinucci, S, De Lalla, F, Tositti, G, Resta, F, Chimienti, A, Lepri, A Cozzi, and Phillips, AN

Published
2001
Full Text
View/download PDF

35. [Ceftriaxone, a long-acting cephalosporin. Microbiological, kinetic and clinical study]

Author

Ml, Soranzo, Capra E, Gc, Angela, Eandi M, Salassa B, Pier Luigi Lollini, Musso E, Pizzo L, Spezia C, and Di Nola F

Subjects
Adult, Male, Clinical Trials as Topic, Adolescent, Ceftriaxone, Cefotaxime, Middle Aged, Staphylococcal Infections, Gram-Positive Bacteria, Klebsiella Infections, Kinetics, Child, Preschool, Streptococcal Infections, Gram-Negative Bacteria, Humans, Female, Meningitis, Child, Respiratory Tract Infections, Aged, Half-Life
Abstract

Ceftriaxone effectively inhibited 332 out of 452 (73.45%) bacterial strains in vitro tests. 291 out of 365 (79.69%) gram negative and 41 out of 87 (47.12%) gram positive strains were inhibited. The tests showed ceftriaxone to be more effective than cephalothin, cephotaxime, cephuroxime, cephamandol and cephoxitin. Kinetic tests showed that cephtriaxone has a plasmatic half life of 7.25 hrs. 24 hours after administration of a 1000 mg venous bolus the drug was still present in the blood. Urinary elimination over a 24 hr. period amounted to means 486.8 mg (48.68%). The drug has liquor transfer capacity. 37 of the 38 patients treated showed complete clinical or clinicobacteriological cure. Improvement was noted in the 38th.

Published
1983

37. Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART),Sopravvivenza, progressione in AIDS e livello di immunosoppresione in persone HIV-positive prima e dopo l'introduzione della terapia antiretrovirale di combinazione con tre o più farmaci (HAART)

Author

Pezzotti, P., Dorrucci, M., Donisi, A., Cusini, M., Mazzarello, G., Andrea De Luca, Salassa, B., Ursitti, M. A., Giuliani, M., and Rezza, G.

40. Risk factors for woman-to-man sexual transmission of the human immunodeficiency virus

Author

Nicolosi, A., Musicco, M., Saracco, A., Lazzarin, A., Angarano, G., Arici, C., Leite, M. L. C., Costigliola, P., Gafà, S., Gasparini, M., Gavazzeni, G., Gervasoni, C., Roberto Luzzati, Magnani, G., Moroni, M., Pristerà, R., Puppo, F., Salassa, B., Sinicco, A., Stellini, R., Tirelli, U., Turbessi, G., Vigevani, G. M., and Zerboni, R.

47. Incidence and consequences of pregnancy in women with known duration of HIV infection

Author

Alliegro, M.B., Dorrucci, M., Phillips, A.N., Pezzotti, P., Boros, S., Zaccarelli, M., Pristera, R., Rezza, G., Lepri, A.C., Sinicco, A., Tarantini, G., Angarano, G., Buccoliero, G., Lazzarin, A., Aiuti, F., Salassa, B., Castelli, F., and Viale, P.

Subjects
HIV infection in pregnancy -- Development and progression
Abstract

Alliegro, M.B.; Dorrucci, M.; Phillips, A.N.; Pezzotti, P.; Boros, S.; Zaccarelli, M.; Pristera, R.; Rezza, G.; Lepri, A.C.; Sinicco, A.; Tarantini, G.; Angarano, G.; Buccoliero, G.; Lazzarin, A.; Aiuti, F.; [...]

Published
1998

48. How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study

Author

Petrucci, A., Dorrucci, M., Alliegro, M.B., Pezzotti, P., Rezza, G., Sinicco, A., Lazzarin, A., Angarano, G., Lepri, A.C., Muratori, S., Tarantini, G., Buccoliero, G., Zaccarelli, M., Salassa, B., Castelli, F., Viale, P., and Canessa, A.

Subjects
HIV infection -- Physiological aspects
Abstract

Petrucci, A.; Dorrucci, M.; Alliegro, M.B.; Pezzotti, P.; Rezza, G.; Sinicco, A.; Lazzarin, A.; Angarano, G.; Lepri, A.C.; Muratori, S.; Tarantini, G.; Buccoliero, G.; Zaccarelli, M.; Salassa, B.; Castelli, F.; [...]

Published
1997

49. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups

Author

Dorrucci, M., Pezzotti, P., Phillips, A.N., Alliegro, M.B., Rezza, G., Boros, S., Lepri, A.C., Sinicco, A., Angarano, G., Tarantini, G., Salassa, B., Castelli, F., Pristera, R., Gafa, S., Colangeli, V., Viale, P., Barbanera, M., and Zaccarelli, M.

Subjects
AIDS (Disease) -- Development and progression, HIV infection -- Drug therapy, Zidovudine -- Health aspects, Drug addicts -- Health aspects
Abstract

Dorrucci, M.; Pezzotti, P.; Phillips, A.N.; Alliegro, M.B.; Rezza, G.; Boros, S.; Lepri, A.C.; Sinicco, A.; Angarano, G.; Tarantini, G.; Salassa, B.; Castelli, F.; Pristera, R.; Gafa, S.; Colangeli, V.; [...]

Published
1997

50. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus

Author

Alliegro, M.B., Dorrucci, M., Pezzotti, P., Rezza, G., Sinicco, A., Barbanera, M., Castelli, F., Tarantini, G., Petrucci, A., Lepri, A.C., Angarano, G., Buccoliero, G., Zaccarelli, M., Salassa, B., Tomasoni, L., Ricchi, E., Gafa, S., and Viale, P.

Subjects
AIDS (Disease) -- Development and progression, Shingles (Disease) -- Complications
Abstract

Alliegro, M.B.; Dorrucci, M.; Pezzotti, P.; Rezza, G.; Sinicco, A.; Barbanera, M.; Castelli, F.; Tarantini, G.; Petrucci, A.; Lepri, A.C.; Angarano, G.; Buccoliero, G.; Zaccarelli, M.; Salassa, B.; Tomasoni, L.; [...]

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results